CHIH


MSCI China Health Care ETF

Fund Summary

The Global X MSCI China Health Care ETF (CHIH) seeks to invest in large- and mid-capitalization segments of the MSCI China Index that are classified in the Health Care Sector as per the Global Industry Classification System (GICS).

Fund Objective

The Global X MSCI China Health Care ETF (CHIH) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI China Health Care 10/50 Index.

Why CHIH?

Targeted Exposure

CHIH is a targeted play on the Health Care Sector in China – the world’s second largest economy by GDP.

ETF Efficiency

In a single trade, CHIH delivers access to dozens of health care companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.

All Share Exposure

The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings, among others.

Fund Details As of 8/10/20

Key Facts

Ticker CHIH
Inception Date 12/7/18
CUSIP 37954Y541
ISIN US37954Y5419
Bloomberg Index Ticker NU722071
Primary Exchange NYSE Arca
Number of Holdings 81

Stats & Fees

Net Assets $8,661,891
NAV $24.75
Shares Outstanding 350,002
Total Expense Ratio 0.66%

Distributions

30-Day SEC Yield 0.09%
Distribution Frequency Semi-Annually

Fund Prices As of 8/10/20

NAV Price
Net Asset Value $24.75 Closing Price $24.84
Daily Change -$0.38 -1.50% Daily Change -$0.22 -0.88%

Performance History

Cumulative %

Data as of month-end (7/31/20)

Fund NAV Closing Price Index
Year-to-Date 41.55% 41.04% 42.22%
1 Month 6.98% 5.51% 7.10%
3 Months 27.92% 30.06% 28.25%
6 Months 43.67% 41.85% 40.95%
Since Inception 67.81% 67.20% 69.98%

Avg Annualized %

Data as of month-end (7/31/20)

Fund NAV Closing Price Index
1 Year 55.38% 55.40% 56.77%
Since Inception 36.91% 36.61% 37.94%

Avg Annualized %

Data as of quarter-end (6/30/20)

Fund NAV Closing Price Index
1 Year 52.01% 53.47% 53.26%
Since Inception 33.34% 34.21% 34.35%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized Return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Fund Characteristics As of 8/10/20

Return on Equity 11.10%
Weighted Avg. Market Cap 13,341 M
2019 2020
Price-to-earnings 40.24 36.96
Price-to-book value 4.26 3.93

Source: AltaVista Research, LLC

Fund Risk Stats As of 8/10/20

Versus Beta
S&P 500 0.71
MSCI EAFE 0.76
MSCI Emg. Mkts 0.74
Standard Deviation 26.50%

Source: AltaVista Research, LLC

Top 10 Holdings

As of 8/10/20
Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
9.21 2269 HK WUXI BIOLOGICS CAYMAN INC BZ3C3R5 21.47 37,140 797,411.16
8.63 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 1.21 618,400 747,646.25
7.62 1093 HK CSPC PHARMACEUTI 6191997 2.01 329,180 660,041.96
7.03 241 HK ALIBABA HEALTH BRXVS60 2.64 230,900 609,262.34
4.83 1066 HK SHANDONG WEIG-H 6742340 2.66 157,400 418,368.56
4.42 1801 HK INNOVENT BIOLOGICS INC BGR6KX5 6.20 61,700 382,530.13
4.19 1833 HK PING AN HEALTHCA BDRYVB3 16.19 22,400 362,726.12
3.52 2359 HK WUXI APPTEC CO LTD-H BGHH0L6 15.51 19,640 304,602.20
3.24 600276 C1 JIANGSU HENGRU-A BP3R369 13.04 21,480 280,196.72
2.67 ZLAB ZAI LAB LTD-ADR BD9GVY0 79.65 2,898 230,825.70
Holdings are subject to change.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHIH is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Closing price returns do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by MSCI, nor does MSCI make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with MSCI.